BACKGROUND Glioblastoma is the most common type of brain tumor and is invariably fatal,with a mean survival time of 8-15 mo for recently diagnosed tumors,and a 5-year survival rate of only 7.2%.The standard treatment ...BACKGROUND Glioblastoma is the most common type of brain tumor and is invariably fatal,with a mean survival time of 8-15 mo for recently diagnosed tumors,and a 5-year survival rate of only 7.2%.The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide.However,the prognosis remains poor and longterm survival is rare.This report aimed to demonstrate a new therapeutic strategy for the treatment of glioblastoma.CASE SUMMARY A patient was referred to the Department of Neurosurgery with an intracranial space-occupying lesion with a maximum diameter of approximately 5 cm.The tumor was compressing functional areas,and the patient accordingly underwent partial resection and concurrent chemoradiotherapy.The imaging and pathological findings were consistent with a diagnosis of glioblastoma with oligodendroglioma differentiation(World Health Organization IV).The patient was finally diagnosed with glioblastoma.However,the patient discontinued treatment due to intolerable side effects,and was prescribed Kangliu pill(KLP)7.5 g three times/d,which he has continued to date.Significant shrinkage of the tumor(maximum diameter reduced from about 3.5 to about 2 cm)was found after 3 mo of KLP therapy,and the tumor was further reduced to about 1 cm after 3 years.The patient’s symptoms of headache,limb weakness,and left hemiplegia were relieved,with no side effects.CONCLUSION KLP has been a successful intervention for glioblastoma, and the current caseindicates that traditional Chinese medicine may offer effective alternativetherapies for glioblastoma.展开更多
目的运用网状meta分析评价口服中成药联合阿维A治疗寻常性银屑病(PV)的效果。方法检索中国知网、维普网、万方数据库、PubMed、EMbase、Web of Science中应用口服中成药联合阿维A治疗PV的随机对照试验(RCT),检索时间为建库至2022年3月...目的运用网状meta分析评价口服中成药联合阿维A治疗寻常性银屑病(PV)的效果。方法检索中国知网、维普网、万方数据库、PubMed、EMbase、Web of Science中应用口服中成药联合阿维A治疗PV的随机对照试验(RCT),检索时间为建库至2022年3月。对纳入文献进行筛选、资料提取和质量评价,采用Stata 14.0进行网状meta分析。结果最终纳入38项RCT,涉及12种中成药,受试者3695例。网状meta分析结果显示,口服中成药联合阿维A的有效率、银屑病面积和严重程度指数(PASI)均优于单纯使用阿维A或同时联合其他辅助药物(P<0.05)。在有效率方面,润肤止痒胶囊联合阿维A(OR=16.06,95%CI:2.79~92.32)最佳,紫丹银屑颗粒(OR=8.47,95%CI:1.00~71.94)次之;在PASI方面,紫丹银屑颗粒联合阿维A最佳(SMD=-2.25,95%CI:-3.21~-1.28),克银丸次之(SMD=-1.99,95%CI:-2.96~-1.01)。比较-校正漏斗图显示存在发表偏倚风险可能性较小。结论口服中成药联合阿维A治疗PV效果较好,但在临床上仍应结合患者情况谨慎用药。展开更多
基金the Foundation for Beijing Science and Technology Development of TCM,No.JJ2016-10the National Traditional Chinese Medicine Innovative Talents Training Project from Beijing Municipal Science and Technology Commission,No.Z171100001717006.
文摘BACKGROUND Glioblastoma is the most common type of brain tumor and is invariably fatal,with a mean survival time of 8-15 mo for recently diagnosed tumors,and a 5-year survival rate of only 7.2%.The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide.However,the prognosis remains poor and longterm survival is rare.This report aimed to demonstrate a new therapeutic strategy for the treatment of glioblastoma.CASE SUMMARY A patient was referred to the Department of Neurosurgery with an intracranial space-occupying lesion with a maximum diameter of approximately 5 cm.The tumor was compressing functional areas,and the patient accordingly underwent partial resection and concurrent chemoradiotherapy.The imaging and pathological findings were consistent with a diagnosis of glioblastoma with oligodendroglioma differentiation(World Health Organization IV).The patient was finally diagnosed with glioblastoma.However,the patient discontinued treatment due to intolerable side effects,and was prescribed Kangliu pill(KLP)7.5 g three times/d,which he has continued to date.Significant shrinkage of the tumor(maximum diameter reduced from about 3.5 to about 2 cm)was found after 3 mo of KLP therapy,and the tumor was further reduced to about 1 cm after 3 years.The patient’s symptoms of headache,limb weakness,and left hemiplegia were relieved,with no side effects.CONCLUSION KLP has been a successful intervention for glioblastoma, and the current caseindicates that traditional Chinese medicine may offer effective alternativetherapies for glioblastoma.
文摘目的运用网状meta分析评价口服中成药联合阿维A治疗寻常性银屑病(PV)的效果。方法检索中国知网、维普网、万方数据库、PubMed、EMbase、Web of Science中应用口服中成药联合阿维A治疗PV的随机对照试验(RCT),检索时间为建库至2022年3月。对纳入文献进行筛选、资料提取和质量评价,采用Stata 14.0进行网状meta分析。结果最终纳入38项RCT,涉及12种中成药,受试者3695例。网状meta分析结果显示,口服中成药联合阿维A的有效率、银屑病面积和严重程度指数(PASI)均优于单纯使用阿维A或同时联合其他辅助药物(P<0.05)。在有效率方面,润肤止痒胶囊联合阿维A(OR=16.06,95%CI:2.79~92.32)最佳,紫丹银屑颗粒(OR=8.47,95%CI:1.00~71.94)次之;在PASI方面,紫丹银屑颗粒联合阿维A最佳(SMD=-2.25,95%CI:-3.21~-1.28),克银丸次之(SMD=-1.99,95%CI:-2.96~-1.01)。比较-校正漏斗图显示存在发表偏倚风险可能性较小。结论口服中成药联合阿维A治疗PV效果较好,但在临床上仍应结合患者情况谨慎用药。
